JP2002535360A5 - - Google Patents

Download PDF

Info

Publication number
JP2002535360A5
JP2002535360A5 JP2000595674A JP2000595674A JP2002535360A5 JP 2002535360 A5 JP2002535360 A5 JP 2002535360A5 JP 2000595674 A JP2000595674 A JP 2000595674A JP 2000595674 A JP2000595674 A JP 2000595674A JP 2002535360 A5 JP2002535360 A5 JP 2002535360A5
Authority
JP
Japan
Prior art keywords
hydrogen
alkyl
aryl
compound
independently selected
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000595674A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002535360A (ja
Filing date
Publication date
Priority claimed from GBGB9901691.7A external-priority patent/GB9901691D0/en
Application filed filed Critical
Publication of JP2002535360A publication Critical patent/JP2002535360A/ja
Publication of JP2002535360A5 publication Critical patent/JP2002535360A5/ja
Pending legal-status Critical Current

Links

JP2000595674A 1999-01-26 2000-01-26 グルタメート作用性伝達における異常を処置するための2−アダマンタンメタンアミン化合物 Pending JP2002535360A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9901691.7A GB9901691D0 (en) 1999-01-26 1999-01-26 Chemical compounds
GB9901691.7 1999-01-26
PCT/GB2000/000207 WO2000044371A1 (en) 1999-01-26 2000-01-26 2-adamantanemethanamine compounds for treating abnormalities in glutamatergic transmission

Publications (2)

Publication Number Publication Date
JP2002535360A JP2002535360A (ja) 2002-10-22
JP2002535360A5 true JP2002535360A5 (https=) 2007-03-08

Family

ID=10846525

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000595674A Pending JP2002535360A (ja) 1999-01-26 2000-01-26 グルタメート作用性伝達における異常を処置するための2−アダマンタンメタンアミン化合物

Country Status (10)

Country Link
US (1) US6531511B1 (https=)
EP (1) EP1143964B1 (https=)
JP (1) JP2002535360A (https=)
AT (1) ATE262326T1 (https=)
AU (1) AU2116900A (https=)
CA (1) CA2360674A1 (https=)
DE (1) DE60009263T2 (https=)
ES (1) ES2216852T3 (https=)
GB (1) GB9901691D0 (https=)
WO (1) WO2000044371A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0018272D0 (en) * 2000-07-25 2000-09-13 Vernalis Research Limited Chemical compounds IV
DE60143671D1 (de) 2001-06-07 2011-01-27 Sang Christine Behandlung von neuropathischen schmerzen mittels eines n-methyl-d-aspartate (nmda)-rezeptor-antagonists
US7283414B1 (en) * 2006-05-24 2007-10-16 Sandisk 3D Llc Method for improving the precision of a temperature-sensor circuit
WO2008035049A1 (en) * 2006-09-18 2008-03-27 Merz Pharma Gmbh & Co. Kgaa Adamantanyl-(cyclopropyl)-ketones as metabotropic glutamate receptor modulators
ES2341517B1 (es) * 2008-03-28 2011-01-25 Farmalider, S.A Utilizacion de un compuesto inhibidor de la activacion de la enzima erk 1/2 en el tratamiento de enfermedades neurodegenerativas.
PL2578212T3 (pl) * 2010-05-24 2017-01-31 Farmalider Sa Związek hamujący aktywację enzymu Erk 1/2 do zastosowania w leczeniu chorób neurodegeneracyjnych
JP7134173B2 (ja) 2017-06-21 2022-09-09 第一三共株式会社 Ep300/crebbp阻害剤

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL6804065A (https=) * 1968-03-22 1969-09-24
YU36365B (en) * 1974-05-16 1983-06-30 Pliva Pharm & Chem Works Process for preparing alpha-amino-2-adamantyl acetic acid
YU30589A (en) * 1989-02-09 1991-10-31 Imunoloski Z Zagreb New adamantyl containing tripeptides and it's hydrochloride and process for preparing and use
US5334618A (en) * 1991-04-04 1994-08-02 The Children's Medical Center Corporation Method of preventing NMDA receptor-mediated neuronal damage
WO1992017168A1 (en) 1991-04-04 1992-10-15 The Children's Medical Center Corporation Method of preventing nmda receptor-mediated neuronal damage
US6011155A (en) 1996-11-07 2000-01-04 Novartis Ag N-(substituted glycyl)-2-cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
GB9726388D0 (en) 1997-12-12 1998-02-11 Cerebrus Ltd Chemical compounds
US6008240A (en) 1997-12-15 1999-12-28 Gliatech, Inc. 2-(1H-4(5)-imidazoyl) cyclopropyl derivatives
CN1131855C (zh) 1997-12-16 2003-12-24 沃尼尔·朗伯公司 1-取代-1-氨基甲基-环烷衍生物(=加巴喷丁类似物)、其制备及其在治疗神经病方面的用途
GB9802225D0 (en) 1998-02-02 1998-04-01 Cerebrus Ltd Chemical compounds
KR20020060160A (ko) 1999-08-12 2002-07-16 파마시아 이탈리아 에스.피.에이. 3(5)-아미노-피라졸 유도체, 이의 제조 방법 및항종양제로서의 이의 용도
CA2318004A1 (en) 1999-09-15 2001-03-15 Oridigm Corporation Novel polyamine analogues as therapeutic and diagnostic agents
MY125533A (en) 1999-12-06 2006-08-30 Bristol Myers Squibb Co Heterocyclic dihydropyrimidine compounds

Similar Documents

Publication Publication Date Title
CA2373653C (en) New use of compounds as antibacterial agents
JP2003500442A5 (https=)
JP2001526218A5 (https=)
JP2002513793A5 (https=)
JP2004517087A5 (https=)
JP2004532209A5 (https=)
JP2005502635A5 (https=)
JP2002543121A5 (https=)
NO20052914L (no) Terapeutiske forbindelser
JP2003509349A5 (https=)
JP2006501201A5 (https=)
JP2002030084A5 (https=)
JP2002518502A5 (https=)
JP2002527414A5 (https=)
JP2003503449A5 (https=)
EA200501703A1 (ru) Применение производных азетидинкарбоксамида в терапии
KR960701007A (ko) 피롤-아미딘계 화합물 및 약제학적으로 허용 가능한 그 염, 그 제조방법 및 상기 화합물을 포함하는 약제조성물
JP2005505583A5 (https=)
JP2004521150A5 (https=)
JP2002535360A5 (https=)
JP2007515467A5 (https=)
JP2005519885A5 (https=)
JP2002526530A5 (https=)
JP2002539089A5 (https=)
CA2499721A1 (en) Chirale oxazole-arylpropionic acid derivatives and their use as ppar agonists